This $16.5B deal, whose impetus is increasing NVO’s manufacturing capacity for Wegovy, was announced 10 months ago (#msg-173773953); however, the prominence of the obesity-drug sector generated a lot of opposition (#msg-175290291).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”